Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Kaya Miah

Kaya Miah

Kaya Miah




+49 6221 42 2133


+49 6221 42 2397


TP 4



Research Interests

  • Survival analysis
  • Clinical trials
  • Multi-state models

Education and Background

  • DKFZ / Biostatistics since September 2019
  • Semester abroad at School of Mathematics and Statistics, University of Sheffield, England (2017-2018)
  • M.Sc. in Statistics with focus on Biometrics, Dortmund University (2019)
  • B.Sc. in Statistics/Theoretical Medicine, Dortmund University (2016)

Selected Publications

Giesen, N., Chatterjee, M., Scheid, C., Poos, A. M., Besemer, B., Miah, K., Benner, A., Becker, N., Moehler, T., Metzler, I., Khandanpour, C., Seidel-Glaetzer, A., Trautmann-Grill, K., Kortüm, K. M., Müller-Tidow, C., Mechtersheimer, G., Goeppert, B., Stenzinger, A., Weinhold, N., Goldschmidt, H. and Raab, M. S. (2023). A phase II clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. Blood.

Mai, E. K., Huhn, S., Miah, K., Poos, A. M., Scheid, C., Weisel, K. C., Bertsch, U., Munder, M., Berlanga, O., Hose, D., Seckinger, A., Jauch, A., Blau, I. W., Hänel, M., Salwender, H. J., Benner, A., Raab, M. S., Goldschmidt, H., and Weinhold, N. (2023). Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood Cancer Journal, 13(1), 1-9.

Mai, E. K., Miah, K., Bertsch, U., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Munder, M., Lindemann, H. W., Merz, M., Hose, D., Jauch, A., Seckinger, A., Luntz, S., Sauer, S., Fuhrmann, S., Brossart, P., Elmaagacli, A., Goerner, M., Bernhard, H., Hoffmann, M., Raab, M. S., Blau, I. W., Hänel, M., Benner, A., Salwender, H. J. and Goldschmidt, H. for the German-speaking Myeloma Multicenter Group (GMMG) (2020). Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia 35(3), 809-822.

Salwender, H., Elmaagacli, A., Merz, M., Miah, K., Benner, A., Haenel, M., Jehn, C., Mai, E. K., Bertsch, U., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Raab, M. S., Luntz, S. P., Besemer, B., Munder, M., Brossart, P., Fuhrmann, S., Lindemann, H.-W., Weisel, K., Duerig, J. and Goldschmidt, H. (2021). Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. Leukemia 35(10), 3007–3011.

to top
powered by webEdition CMS